Inhibikase Therapeutics (IKT) EBITDA (2020 - 2024)
Historic EBITDA for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.9 million.
- Inhibikase Therapeutics' EBITDA fell 19359.61% to -$12.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$28.6 million, marking a year-over-year decrease of 4543.49%. This contributed to the annual value of -$28.6 million for FY2024, which is 4230.64% down from last year.
- Inhibikase Therapeutics' EBITDA amounted to -$12.9 million in Q4 2024, which was down 19359.61% from -$5.8 million recorded in Q3 2024.
- Over the past 5 years, Inhibikase Therapeutics' EBITDA peaked at -$413921.0 during Q2 2020, and registered a low of -$12.9 million during Q4 2024.
- Over the past 5 years, Inhibikase Therapeutics' median EBITDA value was -$4.5 million (recorded in 2021), while the average stood at -$4.2 million.
- Its EBITDA has fluctuated over the past 5 years, first crashed by 57364.46% in 2021, then surged by 1505.28% in 2024.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' EBITDA stood at -$1.2 million in 2020, then tumbled by 319.83% to -$5.0 million in 2021, then grew by 14.01% to -$4.3 million in 2022, then decreased by 1.58% to -$4.4 million in 2023, then plummeted by 193.6% to -$12.9 million in 2024.
- Its EBITDA was -$12.9 million in Q4 2024, compared to -$5.8 million in Q3 2024 and -$5.1 million in Q2 2024.